Try our Advanced Search for more refined results
Life Sciences - August, 2019
319 articles
- Ohio AG Asks 6th Circ. To Halt Upcoming Opioid Bellwether
- Key Health Care And Pharma Policy Debates To Track This Fall
- Eye Device Maker Can't Sue Ex-Partner's Customers Over IP
- Scientists Ask Justices To Overturn $10.5M Fraud Conviction
- Pet Med Cos. Ask 9th Circ. To Revive Merger Challenge
- Ex-Pharmacy Owner Charged In $5M Fraud Scheme
- Argos Says It's Reached Deal To Get Ch. 11 Back On Track
- Key Questions The Oklahoma Opioid Verdict Didn't Answer
- Target Defeats Suit Over 'Worthless' Biotin Supplements
- Ky. Gov. Wins Fight Over Outside Attys In Opioid Suits
- Rx Info Site Fights To Get Off Pharma Groups' Web Blacklists
- Novartis Whistleblower Attys Slam 'Unjust' $1.4M Fee Award
- Deals Rumor Mill: Apcoa, Blued, Smiths Group
- Drugmaker Fine Shows SEC's Renewed Disclosure Focus
- New Best Practices Under E-Discovery Spoliation Rule
- A District Court Split On Hatch-Waxman Venue Determinations
- Allergan To Pay $5M To Exit Ohio Opioid Bellwethers
- Blood Glucose Meter Row Must Be Arbitrated, Fla. Court Hears
- J&J Aims To Cut Calif. Mesh Marketing Trial Short
- Judge Limits Opioid MDL Experts On Compliance, Marketing
- Amgen Cholesterol Drug Patents Nixed, Undoing Jury Verdict
- Gov't Must Restart Medicare Payments To True Health: Judge
- Fed. Circ. Backs Win For Illumina On Scripps Chemical Patent
- Fed. Circ. OKs Order Blocking Generic Of Allergan Eye Drug
- Split Fed. Circ. Backs PTAB Order Junking IPRs On Remand
- Insys Ch. 11 Case Gets Consumer Privacy Watchdog
- Sony To Sell $754M Olympus Stake Following Activist's Calls
- P&G Cancer Trial Win Withstands Fight Over Barred EBay Talc
- How Law Firms Can Create Content Decision Makers Will Read
- Expecting A Pizza Delivered By Drone? It May Take A While
- 4 NY Cases Forge Post-Cyan Securities Litigation Landscape
- White & Case-Led DIC Inks €985M Deal For BASF Pigment Unit
- Okla.'s $572M Win In J&J Opioid Fight On Shaky Ground
- 9th Circ. Wary Of Intervening In Idaho Hemp Seizure Case
- J&J Unit Gets Breast Implants Defect Suits Tossed
- PTAB Grants Narcan IP Review, Rejects Redundant Petitions
- Attys Behind $1B Syphilis Study Suit Beat Sanctions, For Now
- Freeborn Nabs Ex-Katten Pharma Duo For Chicago IP Practice
- Patients Claim Allergan Covered Up Risks Of Breast Implants
- Ex-LeClairRyan Attys Find Homes In DC And Va.
- Ex-Zimmer Exec Fights To Keep Discharge Claim Alive
- Litigation, Regulation Heating Up For E-Cig Manufacturers
- Chemical Plant Emissions Caused Cancer, Ill. Residents Say
- NJ AG Backs J&J Bid To Toss Shareholder Arbitration Suit
- Fed. Circ. Invalidates 5 Of Mallinckrodt's Inomax Patents
- Docs, Med Practice To Pony Up $1.1M To End Kickback Claims
- Wis. Appeals Court Affirms Colgate's Win In Talc Suit
- Prothena Settles Stock-Drop Suit For $15.75M
- Former Obama Official Stumps For NAFTA 2.0 Passage
- When Shareholders Can Bring Direct Claims In Cayman Court
- 4 Key Takeaways As Historic Opioid Ruling Wallops J&J
- Bayer Denied Fees After $155M Hemophilia Drug IP Verdict
- Chancery Says It Can't Enforce NuVasive Noncompete In Del.
- Asbestos Rarely Causes Cancer In Women, J&J Talc Jury Told
- FDA Decries Erectile Dysfunction Drug Promo In New Warning
- Tufts Grad Student Hits School, Staff With Retaliation Suit
- Religious Parents Can't Get Freeze On NY Vaccination Law
- PE-Backed Shoe Retailer Cole Haan Gears Up For IPO
- 5 Firms Vie For Lead In Latest Teva Investor Suit
- Pa. Justices Urged To OK Venue In $12.5M J&J Mesh Litigation
- Loestrin Buyers Say Splitting Trial In 3 Would Cause Chaos
- Akorn's $30M Investor Deal Over Failed Merger Gets 1st OK
- FTC Fights E-Prescription Co. Bid To Nix Monopoly Case
- Okla. Judge Rules J&J Caused Opioid Crisis, Owes $572M
- US Trustee Skeptical As Aegerion Creditors OK Ch. 11 Plan
- Latham, Fenwick Steer Up To $400M Deal For Biotech Modis
- 5 Firms Shape Amgen's $13.4B Celgene Drug Buy
- Juul Trims But Can't Escape E-Cigarette Labeling Suit
- Ill. Officials Report 1st Possible Death Linked To Vaping
- CVS Says Sentry's Heel-Dragging On Doc Production 'Tactical'
- PTAB Puts U. Of Minn. Reviews On Ice For High Court Appeal
- J&J, Okla. Face Moment Of Truth In Milestone Opioid Trial
- Takeda Unit Can't Undo $155M Loss In Bayer IP Row
- 2 Cannabis Bills Would Benefit Banks, Businesses And Gov't
- Adocia's $1.8B Claim Against Eli Lilly Dies In Arbitration
- Allergan Beats Patient Suits Over Implant Warranty Program
- FTC Cybersecurity Cases Highlight Benefits, Risks Of Settling
- Awaiting Answers On A Post-Bristol-Myers Class Question
- Crafting Motions To Seal After 3rd Circ. Avandia Decision
- SEC Breaks Yearslong Silence On Selective Disclosures
- Mylan Partially Beats Amgen Neulasta Biosimilar Claims
- True Health Says Medicare Withholding Violates Ch. 11 Stay
- Aegerion Pharma's Ex-CEO Objects To Ch. 11 Plan
- 7th Circ. Vacates Illustrator's $3.6M Copyright Damages Award
- ViSalus Can't Decertify Class In $925M Robocall Case
- DOJ Hammers 'Unprecedented' Rejection Of FCA Dismissal
- Teva Beats Nestle Unit's Suit Over Rosacea Cream Patents
- King & Spalding Adds Health Care Pro From Hooper Lundy
- Insys Ch. 11 Sales For Two Drug Lines Approved In Del.
- Deal Reached In Anixa Repriced-Stock Suit In Chancery
- New Clarity On Expert Testimony In Pa. State Courts
- Clinical Stage Therapeutics Group Raises $53M
- Chiasma Investors Want Bond From 'Frivolous' Deal Objectors
- Chinook Raises $65M Series A For Kidney Disease Treatments
- Gilead Challenges HHS' HIV-Prevention Patents
- Pa. Justices Snub Appeal Of $2M J&J Pelvic Mesh Award
- Ohio High Court Revives Wrongful Death Suit Against Amazon
- ADHD Drug Indirect Purchasers Lose Antitrust Class Cert. Bid
- Crypto Addresses Blacklisted In OFAC Fentanyl Sanctions
- Commerce Opens Probe Into Imported Thermoplastic Sheet
- 32 New Lawsuits Filed Against Sterigenics In Ill. State Court
- Dow Corning Settles 22-Year Interest Fight With $172M Payout
- PTAB Will Review 2 Guardant Diagnostic Patents
- Pharmacy Retailers Fight Glenmark's Bid To Exit Zetia MDL
- DOJ Seems Gun-Shy With New FCA Penalty Firepower
- Fed. Circ. Says PTAB Didn't Violate Arthrex's Rights
- Calif. Likely To Have More CEQA 'Projects' Following Ruling
- Feds Look To DC Circ. To Revive Drug Pricing Rule
- CBD Producer Says Ex-VP Lied About Having An Equity Stake
- Biotech Cos. Say Cancer-Killing Cell IP Fight Can Be Litigated
- Conglomerate 3M Seeks $3.3B Bond Sale To Fund Acelity Buy
- 7th Circ. Revives Suit Over PetSmart's 'Prescription' Cat Food
- Litigation Finance Can And Should Protect Its Reputation
- Cancer-Focused Biotech Lands $79.5M Series B Round
- Ex-Medline Chemist's ADA Suit Comes Up Short, Judge Finds
- Considering Disclosure Risks In Sensitive Product Recalls
- Insys Creditors Want More Guarantees In Severance Plan
- Calif. Surgeon Testifies J&J Mesh Has Low Complication Rate
- 9th Circ. Shuts Door On Medtronic Obesity Bias Suit
- NY Parents Can't Keep Vaccine Exemption For Disabled Kids
- FDA Hit With Suit Over E-Cigarette Regulation
- ViSalus, Consumers Brawl Over Decert. Bid In Robocall Suit
- Zimmer Urges ITC To Block Rival's Bone Cements From US
- Drugmaker Pays $200K To End SEC Fight Over Study Leaks
- San Diego Pot Zoning Rules Need Enviro Review, Justices Say
- Jones Day Snags Ex-MoFo Patent Litigation Partner In LA
- 'Shadowy' Co. Can't Ignore Eli Lilly's $20M High Court Appeal
- 8th Circ. Upholds Monsanto's $21.5M Roundup Label Deal
- Fed. Circ.'s Arduous Legal Landscape For Diagnostic Patents
- Endo, Perrigo Strike Deal In Nasal Spray Patent Suit
- Pfizer Says It Shouldn't Be Included In EpiPen Class Cert. Bid
- FDA Accused Of Dodging Food Safety Mandate
- Endo Pays $10M To Exit Opioid MDL Bellwethers
- 5 Firms Steer Elanco's $7.6B Bayer Animal Biz Buy
- California Rests Case In Ethicon Mesh False-Marketing Trial
- Nicotine-Addicted Teen Drops Juul False Ad Suit
- Lead Attys Approved For Opioid MDL 'Negotiation Class'
- 4 Drug Cos. Strike $1.5M Deal In Namenda Pay-For-Delay Suit
- IQVIA Says 'Duplicative' Antitrust Claims Belong In NJ
- J&J Talc Educator Never Saw Asbestos Reports, Jury Hears
- 4 Life Science Cos. Lead 5 IPO Filings Totaling $476M
- Walgreens Not Liable To Crash Victims After Drug Mix-up
- Fresenius Seeks $46M In Del. For Broken Merger Legal Fees
- Class Settlements And The Risks Of Viral Media Attention
- Crisis Messaging To Protect Law Firm Brand And Bottom Line
- Weil's Bid To Intervene In Insys Conflict Faces Opposition
- Chemo MDL Patients Shred Sanofi Bid To Delay Bellwether
- Fed. Circ. Backs Sanofi Cancer Drug IP Win, Delaying Generic
- Fed. Circ. Backs PTAB's Gutting Of Enzo DNA Test Patent
- LabCorp Can't Escape All Claims In Suit Over Lab Test Billing
- Toxic Supplement Suit Lacks Proof, Vitamin Shoppe Says
- New Compliance Steps For Filing Drug Co. Settlements
- Glenmark Wants Out Of Pharmacies' Pay-For-Delay Lawsuits
- SC AG Hits 3 Opioid Distributors With Suit Over Crisis
- Sterigenics Emissions Suits Kicked Back To Ill. State Court
- True Health Creditors Say DIP Terms Guarantee Default
- Breast Implant Co. CEO To Pay $160K Over Offering Omission
- 4th NY Doc Charged With Taking Insys Kickbacks Cops Plea
- Judge Says Bid To Nix Valeant Stock-Drop Suit Unnecessary
- Drugmakers Can't Ax MDL's 'Overarching Conspiracy' Claims
- Will FDA Cigarette Warnings Pass Constitutional Scrutiny?
- Actavis Dooms Exforge Buyers' Pay-For-Delay Claims
- With 'New Rule,' Fed. Circ. Upholds Weight Loss Pill Patent
- PTAB To Review Tissue Graft Patent After LifeNet $35M Win
- $925M Robocall Class Says Decert. Bid Is 'Manifestly Unfair'
- J&J Talc Wasn't Dusty Enough To Cause Cancer, Jury Told
- NY AG Issues 33 Subpoenas In Purdue Pharma Opioid MDL
- What You Should Know About Courtroom Closures
- Deals Rumor Mill: ChemChina, SIX Swiss Exchange, Revlon
- WTO Dispute Roundup: Solar, Sugar Cases Plow Ahead
- Cohen Milstein Seeks Lead In Zimmer Biomet PE Cashout Suit
- True Health Creditors Ask To Join Medicare Withholding Suit
- The 50-Year Evolution Of US Cigarette Warnings
- FDA Unveils New Graphic Warnings For Cigarette Packs
- Teva, AbbVie Face Certified Class Over Niaspan Pay-For-Delay
- Lawmakers Press For Pricing Info From Teva, Mylan, Heritage
- Online Pharmacy Co. Hits Industry Orgs With Antitrust Suit
- DOJ Takes Another Shot At Suboxone Film Fraud Case
- Zimmer Says Ex-Exec Can't Relitigate Discharge Claim
- Quinn Emanuel Nabs Shearman Arbitration Partner In NYC
- Pharma Co. Mallinckrodt Gets Firing Suit Kicked To Arbitration
- Fed. Circ. Backs Sanofi In Prostate Cancer Drug Patent Fight
- Deals Rumor Mill: KKR, OCBC Bank, ExxonMobil
- Customers Win Class Cert. In TCPA Suit Against McKesson
- Invisalign Investors Fight Bid To Ax Suit Over Expiring Patents
- Maker Of Defibrillator Vest To Face Trial In Suit Over Death
- Pharma Wholesalers Strike $7.5M Deal In Drivers' OT Suit
- The Outlook On Drug Pricing And Surprise Billing In Congress
- Protecting Medical Method Patents Via Indirect Infringement
- Eli Lilly Unit Sues Alzheimer's Institute For IP 'Conspiracy'
- J&J Baby Powder 'Never' Had Asbestos, NJ Jury Told
- Risperdal Patient Slams J&J's Bid To Dodge Damages Trial
- Covington Reps Biopharma Co. Landos' $60M Funding Round
- Sanofi, Novo, Lilly Look To Ditch Minn. AG's Insulin Suit
- Mesh Maker Must Face Most Claims In Bellwether Suit
- UK Probes Kohlberg's Purchases Of Packaging Suppliers
- Blue Cross Looks To Duck Heart Monitor Co.'s Revived Suit
- Why I Became A Lawyer: A Seaweed Scientist's Odyssey
- DOJ Enforcement Insights From Poultry Price-Fixing Case
- Patent Opportunities In FDA Bispecific Antibody Guidance
- Ex-MLB Player Gets Time Served For Insider Trading
- Investors' Impax Drug Price-Fixing Suit Fails Again
- How To Counter Jury Reliance On Plaintiff's Damages Ask
- Key Expert In Ethicon Mesh Trial Grilled Over Marketing Study
- Mesh Maker Can't Trim MDL Bellwether Alleging It Hid Dangers
- J&J Pounces On Asbestos Testing Method At NJ Talc Trial
- Glancy Asks To Lead Med. Device Co. Stock-Drop Suit
- Feds Say Insys Needs Consent To Sell Gov't Deals In Ch. 11
- Norton Rose Nabs Perkins Coie Health Care Enforcement Atty
- Shook Hardy Opens Boston Office, Adds 4 Philly Attys
- Akorn Seeks OK On $30M Deal Over Failed Merger
- Pharmas Seek Separate Fraud, Antitrust Trials In Loestrin MDL
- Fla. Nerve Repair Co. Hit With Investor Suit Over Stock Drop
- 3 Best Practices For Patent Claims Against Secret Methods
- Amgen Patents Beat Sandoz Validity Check In Biosimilar Fight
- J&J Disputes Asbestos-Mesothelioma Link At NJ Talc Trial
- Humana Says Acthar's Meteoric Price Hike Cost It $700M
- Fed. Circ. Backs Wins For Eli Lilly Over Cancer Drug Patent
- CBD Co. Lied About Access To Tribal Land, SEC Says
- Zetia Buyers' Pay-For-Delay Lawsuits Will Press On
- Court OKs $65.8M Deal In Cephalon Pay-For-Delay Suit
- Providers Take Another Stab At Syringe Antitrust Suit
- Sens. Slam Novartis-Owned Co. For Hiding Bogus Data
- Fed. Circ. Nixes Labrador Retriever Genetic Test Patent
- Athenex Ruling Helps Clarify FDA Drug Compounding Policy
- Using Global Dossier To Simplify USPTO Disclosure Duty
- Ex-Novartis Exec's Attys Get $1.4M Fees In Whistleblower Suit
- 3rd Circ. Decision Limits Liability Of Board Observers
- Insys Plans $29M CBD And Naloxone Sale In Ch. 11
- What We Know About Opioid MDL Settlement Talks
- Novartis Attys Get Reduced Fees Over Whistleblower's Antics
- Investment Pro Denies Role In $6M Illumina Insider Tips Scam
- 'My Grandmother Could Have Filed This,' Valeant Judge Says
- Med Device Co. Settles FCA Trade Violation Claims For $3.3M
- Gov't Fights Insys Founder's Bid To Delay Sentencing
- Israeli Medical Device Co. Raises $70M In IPO
- 5th Amendment Strategy For Parallel Civil, Criminal Litigation
- What OIG Self-Disclosure Guidance Means For HHS Grantees
- Hospitals Want Claim In Insys Ch. 11 That Could Hit $102B
- Orrick, Goodwin Steer Bayer's $240M BlueRock Buy
- Aetna Faces Suit Over Lumbar Disc Surgery Coverage
- Clients Benefit From Law Firm Expense Growth
- Siemens Set To Buy Cadwalader-Led Robotics Biz For $1.1B
- Top Ethicon Doctor Defends Mesh Warnings In Calif. Trial
- J&J Targets Scientist's Talc Studies In Cancer Trial
- Aceto, 3 Execs Escape Stock-Drop Suit For Now
- Cynosure Gets Quick Win In Suit Over Fat-Reduction System
- Boston Scientific Wins FTC Clearance For £3.3B BTG Deal
- Fed. Circ. Urged To Reconsider Enzo DNA Patent Case
- Fed. Circ. Won't Stay Vimovo Case Despite Looming Generic
- Fired Alcon Sales Rep Says Bias 'Permeated The Workforce'
- Pa. Appeals Court Hints At Backing $70M Risperdal Verdict
- IRS Slams Pot Shop's Bid To Restore $600K Write-Off
- Changing Ethics Rules Is Key To Law Firm Innovation
- 5 Insurance Coverage Questions Raised By Opioid Litigation
- Feds Narrow Insider Trading Case Against Rep. Chris Collins
- Kirkland, Skadden Steer Permira's $2.4B Cambrex Buy
- J&J Fixes On Remark Calling Asbestos In Talc 'Urban Legend'
- Agriculture Startup Raises $89M In Series C Funding Round
- Fed. Circ. Backs ITC's Infringement Ruling On E. Coli Patent
- Novartis Hid Bogus Data, May Face Penalties, FDA Says
- Womble Bond Adds Bracewell IP Pro In Houston
- Allergan Can't Escape Generic Drug Price-Fixing Suit
- DePuy Gets $8.2 Million Patent Judgment Slashed In Half
- Home Depot Hit With Suit Over Roundup Sales
- National Coordinating Counsel: Key To Virtual Mass Tort Team
- Mylan Blasts '11th Hour' Discovery Push In EpiPen Row
- Considering The Current And Future Legality Of CBD
- McKesson Tries To Nix Derivative Suit Over Drug Price-Fixing
- From Roundup To Oatmeal: New Trends In Glyphosate Suits
- Unprecedented Agency Divergence On Antitrust Enforcement
- Opioid MDL Judge Signals Support For 'Negotiation Class'
- Timetable For Opioid MDL Trial 'Entirely Untenable': Drug Cos.
- Ex-FDA Czar Says J&J Mesh Paperwork Left Out Risk Info
- J&J Challenges Scientist's Baby Powder Asbestos Findings
- Discovery Rules Adopted In J&J Talc Supplier Ch. 11 Case
- Smith & Nephew Get Partial Win In Hip Implant MDL
- Hooper Lundy Nabs Jones Day Partner To Spearhead IP Group
- Cooperation Lets Pharma IT Pro Duck Jail In $94M Theft Case
- Imprimis Fails To Nix Jury Award In Allergan False Ad Suit
- Drugmakers Fight To Undo Loestrin Antitrust Class Cert.
- Pfizer Defends Arbitration Pact's Confidentiality Language
- Judging A Book: Castillo Reviews 'Raising The Bar'
- CVS Sued Over Injury From Ear Drop, Eye Drop Mix-Up
- Medical Tech Co. Exits 'Stealth Mode' With $35M Fundraise
- A Chance To Clarify Medical Device Patent Indefiniteness
- FTC Concerns Over Bristol-Myers Deal Raise Questions
- Dissecting The Inherent Tension In Today's TCPA Landscape
- AstraZeneca Hit With Pay-For-Delay Suit Over Seroquel XR
- Allergan To Pay $2.7M To End Certain Generic-Delay Claims
- Zimmer Hit With $7.7M Hip Implant Verdict In Damages Retrial
- Salix Clears Teva's Ulcerative Colitis Drug For 2021 Launch
- Purdue Says Mass. Opioid Suit Sets Dangerous Precedent
- Pa. Justices Snub Appeal Over $2.5M Risperdal Verdict
- Online Pharmacy Says Anthem Illegally Axed It From Network
- FDA Focus: What Foley & Lardner's Practice Chair Is Watching
- Incyte Sues Incysus For Having Too Similar A Name
- EU Ready For WTO Showdown Over Turkish Drug Rules
- Mylan CEO Must Face New EpiPen Deposition, Judge Rules
- J&J Unit Wins Toss Of Suit Over Breast Implants
- How To Get The Most Out Of An Expert Witness
- Ropes & Gray Steers Vapotherm's $45M Follow-On Offering
- J&J, Colgate Cleared In Travel Agent's Talc Case
- 3rd NY Doc Cops Plea In Insys Kickbacks Case
- Fed. Circ. Design Patent Case Can Guide Medical Device Cos.
- DOJ's Bid To Toss Whistleblowers' Gilead FCA Suit Hits Snag
- J&J Expert Says Natural Causes At Fault In Woman's Cancer
- Longfellow Buys Bain Research Triangle Properties For $405M
- Sackler Case Could Blow Up High Court's 'Original' Docket
- Biopharma Co. Says Investor Suit Tries To Go Around Board
- Spencer Fane Continues Growth With 19-Atty Add In Houston
- Janssen Gets Third Co. To Put Off Invokana Generic
- FDA Limits On Vasopressin Compounding Valid, Says Judge
- Trump Ups Pressure On China With Fresh Tariff Threat
- Amgen, Teva Antitrust MDL Over Sensipar Going To Del.
- AVX Can't Shake Greatbatch's $22M Pacemaker Patent Win
- Life Sciences Firm Vida Ventures Closes $600M Fund
- Perrigo Investors Largely Beat Bid To Nix Takeover Suit
- Bankruptcy Courts' Buzzkill Of The Marijuana Industry